Tag: therapy

BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector.

BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector.

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”).

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA^®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.